43 research outputs found
Percutaneous radiofrequency lesions adjacent to the dorsal root ganglion alleviate spasticity and pain in children with cerebral palsy: pilot study in 17 patients
BACKGROUND: Cerebral palsy (CP) may cause severe spasticity, requiring neurosurgical procedures. The most common neurosurgical procedures are continuous infusion of intrathecal baclofen and selective dorsal rhizotomy. Both are invasive and complex procedures. We hypothesized that a percutaneous radiofrequency lesion of the dorsal root ganglion (RF-DRG) could be a simple and safe alternative treatment. We undertook a pilot study to test this hypothesis. METHODS: We performed an RF-DRG procedure in 17 consecutive CP patients with severe hip flexor/adductor spasms accompanied by pain or care-giving difficulties. Six children were systematically evaluated at baseline, and 1 month and 6 months after treatment by means of the Modified Ashworth Scale (MAS), Gross Motor Function Measure (GMFM) and a self-made caregiver's questionnaire. Eleven subsequent children were evaluated using a Visual Analogue Scale (VAS) for spasticity, pain and ease of care. RESULTS: A total of 19 RF-DRG treatments were performed in 17 patients. We found a small improvement in muscle tone measured by MAS, but no effect on the GMFM scale. Despite this, the caregivers of these six treated children unanimously stated that the quality of life of their children had indeed improved after the RF-DRG. In the subsequent 11 children we found improvements in all VAS scores, in a range comparable to the conventional treatment options. CONCLUSION: RF-DRG is a promising new treatment option for severe spasticity in CP patients, and its definitive effectiveness remains to be defined in a randomised controlled trial
Recommended from our members
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases
Recommended from our members
INTERSTITIAL IR-192 IMPLANTATION FOR MALIGNANT BRAIN-TUMORS .1. TECHNIQUES OF DOSIMETRY PLANNING
Recommended from our members
Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience
The treatment results of 37 patients with malignant brain neoplasms treated with a computed-tomography-guided stereotactic iridium-192 implant are reviewed. Of these, 29 patients with high-grade gliomas (20 with glioblastoma multiforme (GBM), nine with anaplastic astrocytoma (AA] received an implant as part of their initial management. The median survival was 14.5 and 15.5 months in the patients with previously untreated GBM and AA, respectively. In those patients with recurrent tumour after external-beam irradiation, durable local control over a year was achieved with implantation. Increasing the total tumour dose from 120 to 160 Gy did not improve survival or local control. Karnofsky Performance Status (KPS) was used as an indicator of quality of life and was seen to decrease with a median interval of 8.5 months following treatment. No severe complications were noted in the entire group of patients treated with this implant procedure
INVESTIGATION OF GLUCURONIC ACID METABOLISM IN HUMAN SUBJECTS
Recent interest in the metabolism of glucuronic acid has been aroused mainly as a result of the real-ization (1) that the conjugation of glucuronic acid is an important step in the metabolism of estrogenic and steroid hormones (2, 3) and of epinephrine (4) and following the reports that glucuronic acid may be useful in arthritis (5). Although the mechanism of formation of glucuronides has been observed chiefly in studies of drug metabolism and has been widely accepted as a process of detoxica-tion, the view is now prevalent (6, 7, 8) that this reaction represents a physiological process which we consider a "metabolic conjugation " (1). Thus, it is believed that exogenous drugs are conjugated with glucuronic acid only by virtue of certain o